1. Cohen J. Th e scientifi c challenge of hepatitis C virus. // Science. 1999. V. 285. P. 26 - 30.
2. Donato F., Boffetta P., Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. // Int J Cancer. 1998, 75 (3): 347-354.
3. Zein N.N. Th e epidemiology and natural history of hepatitis C virus infection. // Cleve Clin J Med. 2003, 70, Suppl 4, S2?S6.
4. Muhlberger N., Schwarzer R., Lettmeier B., et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. // BMC Public Health 2009;9:34.
5. Pimenov N.N. Chulanov V.P. Komarova S.V. i dr. Gepatit S v Rossii: epidemiologicheskaya kharakteristika i puti sovershenstvovaniya diagnostiki i nadzora. // Epidemiologiya i infektsionnye bolezni. 2012. № 3. S. 4 - 10.
6. Yushchuk N.D., Znoiko O.O., Dudina K.R., Shut'ko S.A., Kozina A.N., Safiullina N.Kh., Fedoseeva N.V., Belyi P.A., Lugovskikh E.A., Ogarev V.V., Rakhmanova A.G., Khubutiya M.Sh., Yakushechkina N.A., Pimenov N.N., Chulanov V.P., Chesnokov E.V. Otsenka sotsial'no-ekonomicheskogo bremeni gepatita S v Rossiiskoi Federatsii. // «Epidemiologiya i Vaktsinoprofilaktika». 2013. № 2 (69). S. 18-33.
7. Poynard T., Yuen M.F., Ratziu V., et al. Viral hepatitis C. // Lancet 2003;362:2095-100.
8. Bruno S., Battezzati P.M., Bellati G. et al. Long-term benefi cial eff ects in sustained responders to interferon-alfa therapy for chronic hepatitis C. // J Hepatol. 2001; 34: 748-755.
9. Duchatelle V., Marcellin P., Giostra E. et al. Changes in liver fi brosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. // J Hepatol. 1998; 29: 20-28.
10. Veldt B.J., Saracco G., Boyer N. et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. // Gut. 2004; 53: 1504-1508.
11. Buti M., Esteban R. Long-term outcome aſt er interferon therapy in patients with chronic hepatitis C. // Ann Hepatol. 2007; 6: 267-269.
12. Reddy K.R., Govindarajan S., Marcellin P. et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and infl uence on response to therapy with peginterferon alpha-2 a plus ribavirin. // J Viral Hepat. 2008. 15: 129-136.
13. Yasushi Shiratori et al. Histologic Improvement of Fibrosis in patients with Hepatitis C Who Have Sustained Response to Interferon Therapy. // Annals of internal Medicine. 2000. V. 132 (7), 517-524.
14. Pradat P., Voirin N., Tillmann H. L. et al. Progression to cirrhosis in hepatitis C persons: an age-dependent process. // Liver Int. 2007; 27: 335-339.
15. Pradat P., Tillmann H. L., Sauleda S., Braconier J. H., Saracco G. et al. Longterm follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. // J Viral Hepat. 2007, 14 (8): 556-563.
16. Bruno S., Stroff olini T., Colombo M., Bollani S., Benvegnu L. et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. // Hepatology. 2007, 45 (3): 579-587.
17. Fried M.W., Shiff man M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. // N Engl J Med 2002;347:975-82.
18. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. // Lancet 2001;358:958-65.
19. McHutchison J.G., Lawitz E.J., Shiff man M.L., Muir A.J., Galler G.W. et al. Peginterferon alfa-2 b or alfa-2 a with ribavirin for treatment of hepatitis C infection. // N Engl J Med. 2009, 361 (6): 580-593.
20. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. // N Engl J Med 2009;360:1827-38.
21. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. // N Engl J Med 2009;360:1839-50.
22. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. // N Engl J Med 2011;364:2405-16.
23. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24.
24. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. // N Engl J Med 2010;362:1292-303.
25. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. // N Engl J Med 2011;364:2417-28.
26. Kwo P.Y., Lawitz E.J., McCone J., et al. Effi cacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment naive patients with genotype 1 hepatitis C infection (SPRINT-1): an openlabel, randomised, multicentre phase 2 trial. // Lancet 2010;376:705-16.
27. Poordad F., McCone Jr.J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. // N Engl J Med 2011;364:1195-206.
28. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. // N Engl J Med 2011;364:1207-17
29. Flamm S., Lawitz E., Jacobson I., et al. High Sustained Virologic Responses (SVR) Among Genotype 1 Previous Non-responders and Relapsers to Peginterferon/ Ribavirin when Re-treated With Boceprevir (BOC) Plus Peginterferon Alfa-2a/Ribavirin; EASL Poster Presentation. 2011.
30. FDA. Antiviral Drugs Advisory Committee. http://www.fda.gov/downloads/advisorycom mittees/committees/meeting%20materials/drugs/antiviraldrugsadvisorycommittee/ UCM252562.pdf. accessed December 6, 2011.
31. Boceprevir (Victrelis). European Medicines Agency. Available at: http: // www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002332/human_med_001464.jsp&mid=WC0b01ac058001d124. Accessed November 11, 2011.
32. Telaprevir (Incivo). European Medicines Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002313/human_med_001487.jsp&mid=WC0b01ac058001d124. Accessed November 11, 2011.
33. Ivashkin V.T., Yushchuk N.D., Maevskaya M.V. i dr. Rekomendatsii po diagnostike i lecheniyu vzroslykh bol'nykh gepatitom S. // RZhGGK 2013; 23 (2): 41-70.
34. Grishchenko M., Grieve R.D., Sweeting M.J. et al. Cost-eff ectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. // Int. J. Technol. Assess. Health Care. 2009; 25: 171-180.
35. Shepherd J. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation. // Health Technology Assessment. 2007. 11 (11): iii-106.
36. Wright M., Grieve R., Roberts J. et al. Health benefi ts of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. // Health Technol. Assess. 2006; 10: 1-113, iii.
37. Bennett W.G., Inoue Y., Beck J.R. et al. Estimates of the cost-eff ectiveness of a single course of interferon-alpha 2 b in patients with histologically mild chronic hepatitis C. // Ann. Intern. Med. 1997; 127: 855-865.
38. Kenneth E. Sherman, Steven L. Flamm, Nezam H. Afdhal, David R. Nelson, Mark S. Sulkowski, Gregory T. Everson, Michael W. Fried, Michael Adler, Hendrik W. Reesink, Marie Martin, Abdul J. Sankoh, Nathalie Adda, Robert S. Kauff man, Shelley George, Christopher I. Wright, and Fred Poordad for the ILLUMINATE Study Team Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. // N Engl J Med. 2011; 365: 1014-1024.
39. Boceprevir (Victrelis). European Medicines Agency. Assessment report. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_ assessment_report/human/002332/WC500109789.pdf
40. Bruno S., et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype-1 with advanced fi brosis / cirrhosis: subgroup analysis of SPRINT-2 and RESPOND-2 studies. // J Hepatol 2011;54(Suppl. 1):S4.
41. Prilozhenie k prikazu MZ RF № 163 ot 27.05.2002 «Otraslevoi standart. Sistema standartizatsii v zdravookhranenii RF. Kliniko-ekonomicheskie issledovaniya. Obshchie polozheniya».
42. Yagudina R.I., Kulikov A.Yu., Serpik V.G. Diskontirovanie pri provedenii farmakoekonomicheskikh issledovanii. // Farmakoekonomika. 2009; №4: c.10-13.